Skip to main content

Table 4 Longitudinal studies in populations including sporadic Alzheimer's disease patients

From: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

Study Subjects Mean age at baseline (years) Duration of follow-up (years) Platform and antibodies CV Analyte associated with increased risk conversion to AD Magnitude
Mayeux et al. 1999 [30] 105 CNs
64 CNp
73.4
77.4
3.5 ELISA
6E10
R182
R165
- High baseline Aβ1-42 HR = 3.6-4.0
Mayeux et al. 2003 [27] 365 CNs
86 CNp
75.5
79.3
  ELISA
6E10
R182
R165
- High baseline Aβ1-42 1.9-2.4
van Oijen et al. 2006 [61] 1364 CNs
289 CNp
103 CNp-OD
  8.5 ELISA
6E10
R226
R209
<15% High baseline Aβ1-40
Low baseline Aβ1-42/Aβ1-40
HR = 1.17
HR = 1.82
Graff-Radford et al. 2007 [58] 510 CNs
53 CNp
- 5 ELISA
BAN-50
BA27
BC05
- Low baseline Aβ1-42/Aβ1-40 RR = 2.47-3.08
Lopez et al. 2008 [63] 117 CNs
115 CNp
9 MCIs 33MCIp
78.6
79.9
80.5
79.6
4.5 ELISA - None -
Sundelöf et al. 2008 [62] 608CNs
74 CNp
- 11.2 ELISA
BNT77
BA27
BC05
- Low baseline Aβ1-40 (only in the cohort older than 77 at baseline) HR = 4.9
Schupf 2008 [57] 104 MCIp 1021 CNs 80.7
76.3
4.5 ELISA
6E10
R182
R165
- High baseline Aβ1-42 Decrease of Aβ1-42 Decrease of Aβ1-42/Aβ1-40 HR = 2.3-3.5
HR = 2.6
HR = 3.4
Lambert et al. 2009 [59] 985 CNs
233 CNp
73.8
77.9
4 xMAP INNO-BIA - Low baseline Aβ1-42/Aβ1-40 HR = 2.0
Blasko et al. 2010 [78] 122 CNs
33 CNp
- 5 ELISA INNOTEST <17% High baseline Aβ1-42 OR = 1.7
Hansson et al. 2010 [13]     xMAP INNO-BIA <10% No differences  
Toledo et al. 2011 [10] 162 MCIs
145 MCIp
74.7
74.6
3.0 xMAP INNO-BIA <10% None  
Shah et al. 2012 [60] 590 CNs
53 MCIp
24 MCIp-VaD
- 15.8 ELISA 2G3 21F12 <20% Low baseline Aβ1-40
Low baseline Aβ1-42
HR = 2.1
HR = 1.6
Hansson et al. 2012 [29] 677 CNs 37 MCIp
11 MCIp-VaD
5 MCIp-OD
73.1
77.3
78.9
78.8
5 xMAP INNO-BIA <10% High baseline Aβ1-40 OR = 2.2
  1. AD, Alzheimer's disease; CNs, cognitively normal stable; CNp, cognitively normal progression; CNp-OD, cognitively normal progression to non-AD dementia; CSF, cerebrospinal fluid; HR, hazard ratio; MCIp-OD, mild cognitive impairment, progression to non-AD dementia; MCIp, mild cognitive impairment progressor (to AD); MCIp-VaD, mild cognitive impairment, progression to vascular dementia; MCIs, mild cognitive impairment stable; OD, other dementia; OR, odds ratio; RR, relative risk.